Search research articles
Contact Us
Filters
Showing results (91-100 of 106) with videos related to
Page
of 11
Sort By:
Molecular Cancer Therapeutics
|
July 2, 2014
Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib)
Jessica J Huck, Mengkun Zhang, Jerome Mettetal, et al.
Journal for Immunotherapy of Cancer
|
May 23, 2022
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma
Pavlina Chuntova, Akane Yamamichi, Tiffany Chen, et al.
Research Square
|
February 27, 2024
Targeting <i>CCNE1</i> amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR
Haineng Xu, Erin George, David Gallo, et al.
Molecular Cancer Therapeutics
|
May 22, 2012
MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma
Judy Quiju Shi, Kerri Lasky, Vaishali Shinde, et al.
Nature Communications
|
April 1, 2025
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR
Haineng Xu, Erin George, David Gallo, et al.
Cell Reports
|
August 17, 2022
Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells
Emily Gruber, Joan So, Alexander C Lewis, et al.
Leukemia
|
June 10, 2018
Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia
Samir H Barghout, Parasvi S Patel, Xiaoming Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2011
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays
Mark G Manfredi, Jeffrey A Ecsedy, Arijit Chakravarty, et al.
Journal of Medicinal Chemistry
|
March 16, 2022
Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads
Mingzong Li, Zenon Konteatis, Nelamangala Nagaraja, et al.
Journal of Medicinal Chemistry
|
April 8, 2021
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>MTAP</i> Deletion
Zenon Konteatis, Jeremy Travins, Stefan Gross, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 106) with videos related to
Sort By:
Page
of 11
Molecular Cancer Therapeutics
|
July 2, 2014
Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib)
Jessica J Huck, Mengkun Zhang, Jerome Mettetal, et al.
Journal for Immunotherapy of Cancer
|
May 23, 2022
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma
Pavlina Chuntova, Akane Yamamichi, Tiffany Chen, et al.
Research Square
|
February 27, 2024
Targeting <i>CCNE1</i> amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR
Haineng Xu, Erin George, David Gallo, et al.
Molecular Cancer Therapeutics
|
May 22, 2012
MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma
Judy Quiju Shi, Kerri Lasky, Vaishali Shinde, et al.
Nature Communications
|
April 1, 2025
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR
Haineng Xu, Erin George, David Gallo, et al.
Cell Reports
|
August 17, 2022
Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells
Emily Gruber, Joan So, Alexander C Lewis, et al.
Leukemia
|
June 10, 2018
Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia
Samir H Barghout, Parasvi S Patel, Xiaoming Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2011
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays
Mark G Manfredi, Jeffrey A Ecsedy, Arijit Chakravarty, et al.
Journal of Medicinal Chemistry
|
March 16, 2022
Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads
Mingzong Li, Zenon Konteatis, Nelamangala Nagaraja, et al.
Journal of Medicinal Chemistry
|
April 8, 2021
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>MTAP</i> Deletion
Zenon Konteatis, Jeremy Travins, Stefan Gross, et al.
Page
of 11